Notice Information
Notice Title
BSVI (BaseSpace Variant Interpreter)
Notice Description
Software as a service including development
Lot Information
Lot 1
Software license subscription and services provided via the BSVI
Procurement Information
Under a contract dated 9 February 2016 between Genomic England Limited (GEL) and Illumina Cambridge Limited ("Illumina"), the parties co-developed a product for GEL being the Base Space Variant Interpreter ("BSVI") which is not otherwise available on the market. Under the terms of that agreement Illumina retained certain intellectual property rights in the product, while the cost of the product to GEL reflected GEL's role in co-development. It should be noted therefore that BSVI is a very bespoke product provided by Illumina to Genomics England alone and Illumina will retire the product once GEL no longer has a need for it. The original agreement expired in March 21. In November 2019 Genomics England separately signed a contract with Illumina for the provision of sequencing and related services to support the soon to be implemented NHS Genomic Medicine Service ("GMS") ("Sequencing Contract") which is due to expire on 31 October 2025. In March 2021 Genomics England varied the Sequencing Contract to include the provision of the BSVI product as part of its scope for a period of 18 months. Genomics England has on 6 November 2022 entered into a further amendment to the Sequencing Contract under which BSVI will be provided until expiry of the contract or until such earlier time as GEL confirms its long term strategy for securing decision support for cancer for the GMS with its partner, NHS England and procures an alternative or updated solution to meet the new strategy requirements. We expect this to be for a period between 12 and 24 months. Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Sequencing Contract because additional services from Illumina have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for GEL. The value of the variation is under 50% of the value of the Sequencing Contract. NHS England has confirmed that a functioning decision support system for cancer is essential to the success of the GMS for cancer and no hiatus in these services is possible. Genomics England has very specific requirements for decision support as any product needs to fit in with its internal National Genomics Informatics System pipeline and no off the shelf product is available or viable without significant development. Given the background to BSVI development, an immediate termination would not only have led to a hiatus in service but would cause substantial inconvenience and duplication of costs should a new decision support provider be brought in. A new procurement will require preparation and proper planning to meet the future objectives of the service yet to be agreed with NHS England. In the event that this were to be considered a new contract award, we consider that Regulation 32 (2) (b) of the Public Contract Regulations 2015 would apply in any event for the same reasons. There is no other product available in the market to meet the immediate need and requirements and Illumina holds the IP rights to the product. Any supplier would need to substantially develop its standard product to fit Genomics England's needs. This would include customising release cycles to fit the needs of the NHS. BSVI is a very specific product developed for a single customer. For this reason, there is no genuine competition for the BSVI product on the market today and time will be required for GEL to plan for its ultimate replacement.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-0380b5
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/031805-2022
- Current Stage
- Award
- All Stages
- Award
Procurement Classification
- Notice Type
- Award Notice
- Procurement Type
- Standard
- Procurement Category
- Goods
- Procurement Method
- Limited
- Procurement Method Details
- Award procedure without prior publication of a call for competition
- Tender Suitability
- Not specified
- Awardee Scale
- Large
Common Procurement Vocabulary (CPV)
- CPV Divisions
48 - Software package and information systems
72 - IT services: consulting, software development, Internet and support
-
- CPV Codes
48000000 - Software package and information systems
72000000 - IT services: consulting, software development, Internet and support
Notice Value(s)
- Tender Value
- Not specified
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- £747,520 £500K-£1M
Notice Dates
- Publication Date
- 10 Nov 20223 years ago
- Submission Deadline
- Not specified
- Future Notice Date
- Not specified
- Award Date
- 6 Nov 20223 years ago
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Cancelled
- Awards Status
- Active
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- GENOMICS ENGLAND
- Contact Name
- Not specified
- Contact Email
- supplier.engagement@genomicsengland.co.uk
- Contact Phone
- +44 2078825030
Buyer Location
- Locality
- LONDON
- Postcode
- EC1M 6BQ
- Post Town
- Central London
- Country
- England
-
- Major Region (ITL 1)
- TLI London
- Basic Region (ITL 2)
- TLI4 Inner London - East
- Small Region (ITL 3)
- TLI43 Haringey and Islington
- Delivery Location
- TLI London
-
- Local Authority
- Islington
- Electoral Ward
- Bunhill
- Westminster Constituency
- Islington South and Finsbury
Further Information
Notice URLs
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-0380b5-2022-11-10T11:21:46Z",
"date": "2022-11-10T11:21:46Z",
"ocid": "ocds-h6vhtk-0380b5",
"initiationType": "tender",
"tender": {
"id": "GEL-FP-502-22",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "BSVI (BaseSpace Variant Interpreter)",
"status": "complete",
"classification": {
"scheme": "CPV",
"id": "48000000",
"description": "Software package and information systems"
},
"mainProcurementCategory": "goods",
"description": "Software as a service including development",
"lots": [
{
"id": "1",
"description": "Software license subscription and services provided via the BSVI",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
}
],
"items": [
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "48000000",
"description": "Software package and information systems"
},
{
"scheme": "CPV",
"id": "72000000",
"description": "IT services: consulting, software development, Internet and support"
}
],
"deliveryAddresses": [
{
"region": "UKI"
}
],
"relatedLot": "1"
}
],
"procurementMethod": "limited",
"procurementMethodDetails": "Award procedure without prior publication of a call for competition",
"coveredBy": [
"GPA"
],
"procurementMethodRationaleClassifications": [
{
"scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
"id": "D_TECHNICAL",
"description": "The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons"
},
{
"scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
"id": "D_ADD_DELIVERIES_ORDERED",
"description": "Additional deliveries by the original supplier ordered under the strict conditions stated in the directive"
}
],
"procurementMethodRationale": "Under a contract dated 9 February 2016 between Genomic England Limited (GEL) and Illumina Cambridge Limited (\"Illumina\"), the parties co-developed a product for GEL being the Base Space Variant Interpreter (\"BSVI\") which is not otherwise available on the market. Under the terms of that agreement Illumina retained certain intellectual property rights in the product, while the cost of the product to GEL reflected GEL's role in co-development. It should be noted therefore that BSVI is a very bespoke product provided by Illumina to Genomics England alone and Illumina will retire the product once GEL no longer has a need for it. The original agreement expired in March 21. In November 2019 Genomics England separately signed a contract with Illumina for the provision of sequencing and related services to support the soon to be implemented NHS Genomic Medicine Service (\"GMS\") (\"Sequencing Contract\") which is due to expire on 31 October 2025. In March 2021 Genomics England varied the Sequencing Contract to include the provision of the BSVI product as part of its scope for a period of 18 months. Genomics England has on 6 November 2022 entered into a further amendment to the Sequencing Contract under which BSVI will be provided until expiry of the contract or until such earlier time as GEL confirms its long term strategy for securing decision support for cancer for the GMS with its partner, NHS England and procures an alternative or updated solution to meet the new strategy requirements. We expect this to be for a period between 12 and 24 months. Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Sequencing Contract because additional services from Illumina have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for GEL. The value of the variation is under 50% of the value of the Sequencing Contract. NHS England has confirmed that a functioning decision support system for cancer is essential to the success of the GMS for cancer and no hiatus in these services is possible. Genomics England has very specific requirements for decision support as any product needs to fit in with its internal National Genomics Informatics System pipeline and no off the shelf product is available or viable without significant development. Given the background to BSVI development, an immediate termination would not only have led to a hiatus in service but would cause substantial inconvenience and duplication of costs should a new decision support provider be brought in. A new procurement will require preparation and proper planning to meet the future objectives of the service yet to be agreed with NHS England. In the event that this were to be considered a new contract award, we consider that Regulation 32 (2) (b) of the Public Contract Regulations 2015 would apply in any event for the same reasons. There is no other product available in the market to meet the immediate need and requirements and Illumina holds the IP rights to the product. Any supplier would need to substantially develop its standard product to fit Genomics England's needs. This would include customising release cycles to fit the needs of the NHS. BSVI is a very specific product developed for a single customer. For this reason, there is no genuine competition for the BSVI product on the market today and time will be required for GEL to plan for its ultimate replacement."
},
"awards": [
{
"id": "031805-2022-1",
"relatedLots": [
"1"
],
"title": "BSVI (BaseSpace Variant Interpreter)",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-68155",
"name": "Illumina Cambridge Limited"
}
]
}
],
"parties": [
{
"id": "GB-FTS-8859",
"name": "Genomics England",
"identifier": {
"legalName": "Genomics England"
},
"address": {
"streetAddress": "Dawson Hall, Charterhouse Square",
"locality": "London",
"region": "UKI",
"postalCode": "EC1M 6BQ",
"countryName": "United Kingdom"
},
"contactPoint": {
"telephone": "+44 2078825030",
"email": "supplier.engagement@genomicsengland.co.uk"
},
"roles": [
"buyer"
],
"details": {
"url": "http://www.genomicsengland.co.uk",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "BODY_PUBLIC",
"description": "Body governed by public law"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
},
{
"id": "GB-FTS-68155",
"name": "Illumina Cambridge Limited",
"identifier": {
"legalName": "Illumina Cambridge Limited"
},
"address": {
"locality": "Cambridge",
"region": "UKH",
"postalCode": "CB21 6DF",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-525",
"name": "High Court",
"identifier": {
"legalName": "High Court"
},
"address": {
"locality": "London",
"countryName": "United Kingdom"
},
"roles": [
"reviewBody"
]
}
],
"buyer": {
"id": "GB-FTS-8859",
"name": "Genomics England"
},
"contracts": [
{
"id": "031805-2022-1",
"awardID": "031805-2022-1",
"title": "BSVI (BaseSpace Variant Interpreter)",
"status": "active",
"value": {
"amount": 747520,
"currency": "GBP"
},
"dateSigned": "2022-11-06T00:00:00Z"
}
],
"bids": {
"statistics": [
{
"id": "1",
"measure": "bids",
"relatedLot": "1",
"value": 1
}
]
},
"language": "en"
}